Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Anacor Pharmaceuticals Announces Its Partner GSK Voluntarily Paused Clinical Trials

Published: Tuesday, February 07, 2012
Last Updated: Tuesday, February 07, 2012
Bookmark and Share
Trials paused due to a recently identified microbiological finding in a small number of patients in the Phase 2b trial of GSK '052 for the treatment of complicated urinary tract infections (cUTI).

GSK is in the process of obtaining additional information in order to better understand the data, but will not resume the trials until it has concluded its investigation. Upon completion of the review, GSK will determine next steps regarding the future development of GSK '052.

In addition to the Phase 2b study in cUTI, GSK '052 is currently being evaluated in a Phase 2b study in complicated intra-abdominal infections (cIAI) and two Phase 1 studies in healthy volunteers. While the microbiological finding seen in the cUTI study is not related to the safety of GSK '052, the potential to negatively impact efficacy led GSK to voluntarily suspend enrollment in all four studies. Subjects who are currently enrolled in the ongoing studies may continue at the discretion of the investigator.

"We will work with GSK to better understand this microbiological finding, which we anticipate could take several months," said David Perry, CEO of Anacor Pharmaceuticals. "We respect GSK's decision to pause enrollment in the current studies as we fully investigate the microbiology finding in the Phase 2b cUTI patients."

Anacor licensed GSK '052 to GSK in July 2010 under the companies' ongoing research and development collaboration.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Anacor Pharmaceuticals Announces Preliminary Results from Two Safety Studies
AN2728 studies provide positive results, ointment well tolerated on large body surfaces and sensitive skin.
Wednesday, February 08, 2012
Scientific News
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Editing Gene Mutations in Anemia
Researchers successfully use a new gene editing strategy to correct mutations that cause a form of anemia.
Nanomedicine Aims to Improve HIV Drug Therapies
New research aims to improve the administration and availability of drug therapies to HIV patients using nanotechnology.
Observing Direct Inheritance of Gene-Silencing RNA
Research has allowed for the observation of double-stranded RNA molecule being passed from parent to offspring in roundworms.
Fighting Cancer with Immune Response
New treatment elicits two-pronged immune response that destroys tumors in mice.
First Entirely 3D-printed Organ-on-a-Chip with Integrated Sensors
New approach to manufacturing may allow researchers to rapidly design organs-on-chips that match the properties of a specific disease or individual patient's cells.
Nanoparticles Offer Promising Platform for Flavivirus Treatment
New nanoparticle effectively vaccinated mice against one dengue strain and could be created to target all four.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Ovarian Cancer Insight
Study showed tumours release cytokines to attract macrophages, which secrete growth factors that in turn promote tumour growth.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos